Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer

Int Urol Nephrol. 1998;30(1):41-4. doi: 10.1007/BF02550276.


In this study, we evaluated low dose intravesical bacillus Calmette-Guerin (BCG) therapy following transurethral resection (TUR) in 80 patients with superficial bladder cancer. The patients were divided into two groups. Of the Connaught BCG strain 81 mg was given to 40 patients in Group 1 and 54 mg to the remainder of 40 patients in Group 2. BCG was introduced once a week for 6 weeks. Tumour recurrence was seen in 6 patients in Group 1 and in 10 patients in Group 2. Recurrence rates per month were 0.71 and 1.49, respectively. There was no significant difference in complication rates. These data suggest that while the standard dose (81 mg) intravesical therapy of BCG is more effective than the low dose, there was no significant difference in side effects between the two groups.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Administration, Intravesical
  • Adult
  • Aged
  • BCG Vaccine / administration & dosage*
  • Combined Modality Therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / prevention & control*
  • Prospective Studies
  • Treatment Outcome
  • Urinary Bladder Neoplasms / therapy*


  • Adjuvants, Immunologic
  • BCG Vaccine